America of a famous hospital Scientists by Cancer A cell-killing drug has been developed that destroys solid tumors through ‘targeted chemotherapy‘.
The pill contains a protein, for example, that acts like a ‘blizzard that can shut down an airline’s main hub and thus stop the flow of only planes carrying cancer cells.’
The protein was developed by a research team at City of Hope Hospital, one of the largest cancer research and treatment organizations in the United States.
A molecule called AOH1996 works by targeting the cancer variant of PCNA, a protein important for DNA replication and tumor growth.
Developed over the past two decades, this drug has proven effective in clinical research to treat breast, prostate, brain, ovarian, cervical, skin and lung cancers.
In this study, published in the medical journal ‘Cell Chemical Biology’, this protein was tested on more than 70 cancer cell lines.
This section contains related reference points (Related Nodes field).
The results showed that the AOH1996 molecule selectively killed cancer cells by disrupting the normal reproductive cycle of the cell. The next step is to advance these findings through clinical trials in humans.
Dr Linda Malkas, PhD, Professor of Molecular Diagnostics and Experimental Therapeutics at City of Hope and MT&BA Professor of Molecular Oncology, Ahmadineja said: ‘PCNA is like a large airline terminal hub with a More air gates are included. The data showed that PCNA is uniquely mutated in cancer cells and this fact helped us develop a drug that would target only the mutated form of PCNA in cancer cells. is.’
He added: ‘Our cancer-killing drug is like a blizzard that shuts down a major airline hub only to stop all flights carrying cancer cells.’
According to him: ‘The results have been promising. AOH1996 can inhibit tumor growth as a monotherapy without inducing toxicity in cell and animal models. The investigational chemotherapy is currently in a phase one human clinical trial at City of Hope.’
The study’s lead author, Long Guo, associate research professor in the Department of Molecular Diagnostics at Beckman Research Institute in the City of Hope, added: ‘No drug has ever targeted PCNA therapeutically. was made because it was considered ‘untreatable’ but clearly City of Hope was able to develop an investigational drug to target a challenging protein.’
According to him: ‘We discovered that PCNA is one of the possible causes of increased nucleic acid replication errors in cancer cells. Now that we know the specific part of the problem and can prevent it, we will go deeper to understand the process to develop more personalized and targeted cancer drugs.’
#Breakthrough #cancer #treatment #tumorkilling #drug #discovered
Which types of cancers have shown positive responses to the AOH1996 treatment?
**Interview with Dr. Linda Malkas: A Breakthrough in Targeted Cancer Treatment**
**Editor**: Thank you for joining us today, Dr. Malkas. Your research team at City of Hope Hospital has developed a significant advancement in cancer treatment. Can you explain how the AOH1996 drug works?
**Dr. Malkas**: Absolutely. AOH1996 is designed to target a specific variant of the PCNA protein, which is crucial for DNA replication and tumor growth. Think of PCNA as an airport hub with multiple gates. In cancer cells, this hub is mutated, allowing us to develop a drug that selectively targets and disrupts the cancer cells while sparing healthy ones.
**Editor**: That’s fascinating! You mentioned it acts like a ‘blizzard’ to stop cancer cells. Can you elaborate on that analogy?
**Dr. Malkas**: Certainly! Just like a blizzard can shut down airport operations, our drug effectively halts the activities of cancer cells by disrupting their normal reproductive cycle. This targeted approach helps eliminate solid tumors more efficiently without affecting surrounding healthy tissue.
**Editor**: The research was conducted on over 70 cancer cell lines. What are some of the cancers AOH1996 has been effective against?
**Dr. Malkas**: AOH1996 has shown promising results in treating various types of cancers, including breast, prostate, brain, ovarian, cervical, skin, and lung cancers. The breadth of effectiveness is encouraging for both future research and clinical applications.
**Editor**: What are the next steps for this drug following the positive results from your studies?
**Dr. Malkas**: The next crucial step is to initiate clinical trials in humans. We need to ensure that the drug is safe and effective in a broader population before we can move toward potential approval for general use.
**Editor**: Thank you, Dr. Malkas. It sounds like AOH1996 could be a game changer in cancer treatment.
**Dr. Malkas**: Thank you for having me! We’re hopeful that our work will lead to new, more effective therapies that improve outcomes for cancer patients.
**Editor**: We look forward to following this exciting development!